JP2024515827A5 - - Google Patents

Info

Publication number
JP2024515827A5
JP2024515827A5 JP2023566512A JP2023566512A JP2024515827A5 JP 2024515827 A5 JP2024515827 A5 JP 2024515827A5 JP 2023566512 A JP2023566512 A JP 2023566512A JP 2023566512 A JP2023566512 A JP 2023566512A JP 2024515827 A5 JP2024515827 A5 JP 2024515827A5
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
modified
acid according
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515827A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026805 external-priority patent/WO2022232442A2/en
Publication of JP2024515827A publication Critical patent/JP2024515827A/ja
Publication of JP2024515827A5 publication Critical patent/JP2024515827A5/ja
Pending legal-status Critical Current

Links

JP2023566512A 2021-04-28 2022-04-28 多重CRISPR/Cas9媒介標的遺伝子活性化システム Pending JP2024515827A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181059P 2021-04-28 2021-04-28
US63/181,059 2021-04-28
PCT/US2022/026805 WO2022232442A2 (en) 2021-04-28 2022-04-28 Multiplex crispr/cas9-mediated target gene activation system

Publications (2)

Publication Number Publication Date
JP2024515827A JP2024515827A (ja) 2024-04-10
JP2024515827A5 true JP2024515827A5 (cg-RX-API-DMAC7.html) 2025-05-20

Family

ID=83848892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566512A Pending JP2024515827A (ja) 2021-04-28 2022-04-28 多重CRISPR/Cas9媒介標的遺伝子活性化システム

Country Status (7)

Country Link
US (1) US20240209354A1 (cg-RX-API-DMAC7.html)
EP (1) EP4330375A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515827A (cg-RX-API-DMAC7.html)
CN (1) CN117580941A (cg-RX-API-DMAC7.html)
AU (1) AU2022267320A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218209A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022232442A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025111340A1 (en) * 2023-11-20 2025-05-30 William Marsh Rice University Engineered extrachromosomal nucleic acids and methods of use thereof
WO2025227064A1 (en) * 2024-04-26 2025-10-30 Renasci Biotechnologies, Inc. Genomic editing methods to treat cardiovascular disease, and compositions for use in practicing the same
CN119020323A (zh) * 2024-09-29 2024-11-26 中国农业科学院作物科学研究所 一种融合外切酶的CRIPSR/Cas12i3小麦基因编辑体系
CN120041508A (zh) * 2025-02-20 2025-05-27 徐州医科大学 过表达six2基因的制剂在制备促进小胶质细胞表型转化的试剂中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0117481Y1 (ko) 1994-12-30 1998-07-15 박기영 자동차 열교환기의 기밀구조
US6110743A (en) 1995-02-10 2000-08-29 The Regents Of The University Of California Development and use of human pancreatic cell lines
US20100122355A1 (en) 2008-07-16 2010-05-13 Neal Paragas Transgenic Reporter Mouse and Method for Use
JP6793547B2 (ja) * 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
WO2016164797A1 (en) 2015-04-08 2016-10-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activatable crispr/cas9 for spatial and temporal control of genome editing
EP3417062B1 (en) * 2016-02-15 2024-06-26 Temple University - Of The Commonwealth System of Higher Education Excision of retroviral nucleic acid sequences
AU2018393050A1 (en) * 2017-12-21 2020-06-18 Bayer Healthcare Llc Materials and methods for treatment of Usher Syndrome Type 2A
WO2019236081A1 (en) * 2018-06-06 2019-12-12 Salk Institute For Biological Studies Targeted gene activation using modified guide rna
CN114616002A (zh) * 2019-09-13 2022-06-10 瑞泽恩制药公司 使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控

Similar Documents

Publication Publication Date Title
US20260009050A1 (en) Anellosomes for delivering secreted therapeutic modalities
JP2024083479A5 (cg-RX-API-DMAC7.html)
JP2020508685A5 (cg-RX-API-DMAC7.html)
WO2024119625A1 (zh) 双链rna的合成方法及rna连接酶在双链rna合成中的应用
JP2023544683A5 (cg-RX-API-DMAC7.html)
JP2024531486A (ja) 環状rnaを調製するための構築物及び方法
FI4211231T3 (fi) Peptidimodifioitu aav-kapsidi
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
JP2021507682A5 (cg-RX-API-DMAC7.html)
JP2024520528A5 (cg-RX-API-DMAC7.html)
CA3121528A1 (en) Anellosomes and methods of use
CA3119339A1 (en) Anellosomes for delivering intracellular therapeutic modalities
US20250223592A1 (en) Compositions and methods for circular rna affinity purification
CA3119814A1 (en) Anellosomes for delivering protein replacement therapeutic modalities
CR20230363A (es) Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal
WO2019094669A2 (en) Self-assembling protein structures and components thereof
JP2024523394A5 (cg-RX-API-DMAC7.html)
JP2024525602A (ja) 切断不活性Cas12F1、切断不活性Cas12F1ベースの融合タンパク質、これを含むCRISPR遺伝子調節システム、その製造方法及び用途
WO2019079819A1 (en) COMPOSITION AND METHOD FOR ACTIVATION OF LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV)
JP2026500040A (ja) 複合体及びその使用
WO2023227124A1 (zh) 一种构建mRNA体外转录模板的骨架
WO2024251229A9 (zh) Cas酶及其系统和应用
JP2024503091A5 (cg-RX-API-DMAC7.html)
TW202221126A (zh) 用於鑑別及特徵化指環病毒之方法及其用途
CN117580941A (zh) 多重CRISPR/Cas9介导的靶基因激活系统